24Jun 2023
Serum uric acid lowering and effects of sodium‐glucose cotransporter‐2 inhibitors on gout: A meta‐analysis and meta‐regression of randomized controlled trials

Serum uric acid lowering and effects of sodium‐glucose cotransporter‐2 inhibitors on gout: A meta‐analysis and meta‐regression of randomized controlled trials

SGLT2 inhibitors, a class of drugs used to treat type 2 diabetes and heart failure, have been found to significantly reduce the risk of gout in individuals with these conditions. The use of SGLT2 inhibitors was associated with a reduced risk of gouty arthritis and gout flares, as well as a lower likelihood of starting anti-gout medications. The study also revealed that the benefits of SGLT2 inhibitors were not influenced by baseline serum uric acid levels or the lowering of uric acid during treatment.

  • #endo-diabetology

Like

Save

Share